<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04462796</url>
  </required_header>
  <id_info>
    <org_study_id>1567451</org_study_id>
    <nct_id>NCT04462796</nct_id>
  </id_info>
  <brief_title>The Effect of Magnesium Citrate Supplementation in Restless Legs Syndrome (RLS)</brief_title>
  <acronym>RLS</acronym>
  <official_title>The Effect of Magnesium Citrate Supplementation in Patients With Restless Legs Syndrome (RLS) - An Open Label, Prospective, Non Placebo Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OSF Healthcare System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OSF Healthcare System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The expected results of this study will have a significant impact on the treatment of RLS/WED&#xD;
      patients. Magnesium supplementation (if proven to be beneficial) can be utilized as an&#xD;
      inexpensive, safer, biologically plausible alternative to dopamine agonists and α2δ&#xD;
      calcium-channel ligands.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, prospective, non-placebo controlled pilot study. 15 subjects with a&#xD;
      diagnosis of restless legs syndrome (ICSD-3 diagnostic criteria) will be recruited from OSF&#xD;
      Healthcare Saint Francis Medical Center sleep center and Illinois Neurological Institute.&#xD;
      RLS/WED patients who meet inclusion and exclusion criteria during the initial clinic visit&#xD;
      will be offered study participation. Standard treatment options will be discussed prior to&#xD;
      the enrollment. Patients will be reassured that not participating in the study will not&#xD;
      affect the future care they receive at OSF HealthCare. The potential risks and benefits of&#xD;
      the study will be provided and, if the patient is interested, informed consent will be&#xD;
      obtained. If the subject withdraws consent or does not finish both pre and post evaluation,&#xD;
      we will replace the subject with another new recruit. The subject will come to the clinic for&#xD;
      2 visits, a pre-magnesium visit and a post-magnesium visit. Following the completion of the&#xD;
      pre-magnesium visit, the subject will be given 200 mg elemental magnesium daily (will be&#xD;
      instructed to take with food at dinner) for 8 weeks. Both Visits the following study&#xD;
      procedures will be performed: magnesium level, (International Restless Legs Syndrome) IRLS&#xD;
      scale, Kohnen Restless Legs Syndrome Quality of Life Instrument (KRLS-QOL) scale and&#xD;
      (Multiple Suggested Immobilization (MSI) test. The post magnesium visit will be schedule at&#xD;
      the completion of the 8 week dose of magnesium.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Pilot study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Improvement of Restless Legs Symptoms measured by the International Restless Legs Syndrome Scale (IRLS)</measure>
    <time_frame>Completion of Study participation at 8 weeks</time_frame>
    <description>International Restless Leg Syndrome Scale. (IRLS) is a 10 question scale that subjects rate on a scale of 0-4; RLS can be classified as mild, moderate, severe and very severe, if the score is 0-10 (mild), 11-20 (moderate), 21-30 (severe) or 31-40 (very severe) respectively. The lower score reflects less symptom burden. Minimum score is 0 with a Maximum of 40.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Improvement of Restless Legs Symptoms measured by the Kohnen Kohnen Restless Legs Syndrome Quality of Life Instrument (KRLS QOL)</measure>
    <time_frame>Completion of Study participation at 8 weeks</time_frame>
    <description>Kohnen Restless Legs Syndrome Quality of Life instrument (KRLS QOL) is a self-administered validated patient-reported outcome measure with 12 questions that assess the quality of life in RLS patients. Scores range from 0-60.The lower score represents less impact of RLS symptoms on quality of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Improvement of Restless Legs Symptoms: Multiple Suggested Immobilization test (MSI) Score</measure>
    <time_frame>Completion of Study participation at 8 weeks</time_frame>
    <description>Reduction in Multiple Suggested Immobilization test (MSI) discomfort Scores, range: 0-10, with a maximum total sum of 60 per hour. Three 1 hour trials will be conducted. Periodic limb movements during wakefulness will also be measured. Periodic limb movement index (PMLI) reflects periodic limb movements per hour. PMLI value of 0 indicates absence of limb movements and higher scores are often seen in patients with severe RLS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of magnesium levels with Kohnen Restless Legs Syndrome Quality of Life Instrument (KRLS) and Multiple Suggested Immobilization test (MSI) scores</measure>
    <time_frame>Completion of Study participation at 8 weeks</time_frame>
    <description>Assessment of Magnesium level, lab value will be assess. Normal values range from 1.6 - 2.6 mg/dl. The rationale of measuring serum magnesium level is to analyze whether serum magnesium levels correlate with other subjective and objective RLS outcome measures</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <arm_group>
    <arm_group_label>Magnesium Citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnesium Citrate given orally taken once daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Magnesium Citrate</intervention_name>
    <description>Magnesium Citrate 200 mg daily</description>
    <arm_group_label>Magnesium Citrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18 and 89.&#xD;
&#xD;
          2. Treatment naïve patients (who are not taking RLS medications for at least 1 year)&#xD;
             without coexisting untreated OSA.&#xD;
&#xD;
          3. Diagnosed with RLS based on ICSD -3 criteria&#xD;
&#xD;
          4. INI OSF Sleep medicine outpatient clinic patients.&#xD;
&#xD;
          5. Patients with the ability to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are currently taking magnesium supplements or took magnesium supplements&#xD;
             in the last 3 months.&#xD;
&#xD;
          2. Patients not on a stable dosage of medications ( patients requiring dosage changes)&#xD;
             that can cause PLMs or worsen RLS will be excluded ( medications include&#xD;
             antidepressants such as SSRIs, SNRIs and TCAs and Antihistamines such as Benadryl and&#xD;
             Allegra, etc)&#xD;
&#xD;
          3. Patients with a history of chronic kidney disease or end-stage renal disease on&#xD;
             Hemodialysis&#xD;
&#xD;
          4. Patients with known allergies to magnesium citrate&#xD;
&#xD;
          5. Patients with congestive heart failure with an ejection fraction less than 40%,&#xD;
             bradycardia with a resting heart rate below 60 and systolic blood pressure less than&#xD;
             90 mm of Hg.&#xD;
&#xD;
          6. Patients with diarrhea&#xD;
&#xD;
          7. Patients on gabapentin or pregabalin for pain syndromes&#xD;
&#xD;
          8. Pregnancy. (Absence of pregnancy will be determined via subject self-reporting only.&#xD;
             Subject self-reporting of the absence of pregnancy is sufficient screening because the&#xD;
             dosage of Magnesium supplement that subjects will be consuming during the study is&#xD;
             well below the NIH Tolerable Upper Intake Levels for pregnancy [see &quot;Dietary&#xD;
             Recommendations&quot; below], and has been shown to cause no fetal abnormalities or&#xD;
             pregnancy complications at the dosage patients will consume for the study. Subjects&#xD;
             will be encouraged to practice appropriate measures to avoid pregnancy throughout the&#xD;
             entirety of their study participation).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sasikanth Gorantla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OSF Healthcare Saint Francis Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashwath R Ravisankar, MBBS</last_name>
    <phone>(309) 624-5422</phone>
    <email>ashwath.r.ravisankar@osfhealthcare.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kimberly L Hartwig, RN, BSN</last_name>
    <phone>(309) 655-4229</phone>
    <email>kimberly.hartwig@osfhealthcare.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OSF Healthcare Illinois Neurological Institute</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Praneeth K Chebrolu, MBBS</last_name>
      <phone>309-624-5419</phone>
      <email>praneeth.k.chebrolu@osfhealthcare.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://aasm.org/clinical-resources/scoring-manual/</url>
    <description>Manual used for scoring sleep and associated events</description>
  </link>
  <reference>
    <citation>Pratt DP. Restless Legs Syndrome/Willis-Ekbom Disease and Periodic Limb Movements: A Comprehensive Review of Epidemiology, Pathophysiology, Diagnosis and Treatment Considerations. Curr Rheumatol Rev. 2016;12(2):91-112. doi: 10.2174/1573403x12666160223120340.</citation>
    <PMID>26902775</PMID>
  </reference>
  <reference>
    <citation>Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997 Jan;12(1):61-5. doi: 10.1002/mds.870120111.</citation>
    <PMID>8990055</PMID>
  </reference>
  <reference>
    <citation>Coleman RM, Miles LE, Guilleminault CC, Zarcone VP Jr, van den Hoed J, Dement WC. Sleep-wake disorders in the elderly: polysomnographic analysis. J Am Geriatr Soc. 1981 Jul;29(7):289-96. doi: 10.1111/j.1532-5415.1981.tb01267.x.</citation>
    <PMID>7240617</PMID>
  </reference>
  <reference>
    <citation>Scofield H, Roth T, Drake C. Periodic limb movements during sleep: population prevalence, clinical correlates, and racial differences. Sleep. 2008 Sep;31(9):1221-7.</citation>
    <PMID>18788647</PMID>
  </reference>
  <reference>
    <citation>Garcia-Borreguero D, Guitart X, Garcia Malo C, Cano-Pumarega I, Granizo JJ, Ferre S. Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis. Sleep Med. 2018 May;45:94-97. doi: 10.1016/j.sleep.2018.02.002. Epub 2018 Feb 24.</citation>
    <PMID>29680437</PMID>
  </reference>
  <reference>
    <citation>Leu-Semenescu S, Petiau C, Charley Monaca C, Dauvilliers Y. French consensus: Augmentation syndrome in restless legs syndrome. Rev Neurol (Paris). 2018 Sep-Oct;174(7-8):532-539. doi: 10.1016/j.neurol.2018.06.004. Epub 2018 Jul 25.</citation>
    <PMID>30055794</PMID>
  </reference>
  <reference>
    <citation>Ito E, Inoue Y. [The International Classification of Sleep Disorders, third edition. American Academy of Sleep Medicine. Includes bibliographies and index]. Nihon Rinsho. 2015 Jun;73(6):916-23. Japanese.</citation>
    <PMID>26065120</PMID>
  </reference>
  <reference>
    <citation>Ferini-Strambi L, Aarskog D, Partinen M, Chaudhuri KR, Sohr M, Verri D, Albrecht S. Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med. 2008 Dec;9(8):874-81. doi: 10.1016/j.sleep.2008.09.001. Epub 2008 Oct 25.</citation>
    <PMID>18952497</PMID>
  </reference>
  <reference>
    <citation>Giorgi L, Asgharian A, Hunter B. Ropinirole in patients with restless legs syndrome and baseline IRLS total scores &gt;/= 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension. Clin Ther. 2013 Sep;35(9):1321-36. doi: 10.1016/j.clinthera.2013.06.016. Epub 2013 Aug 9.</citation>
    <PMID>23938061</PMID>
  </reference>
  <reference>
    <citation>Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, Trenkwalder C; International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003 Mar;4(2):121-32. doi: 10.1016/s1389-9457(02)00258-7.</citation>
    <PMID>14592342</PMID>
  </reference>
  <reference>
    <citation>Abetz L, Arbuckle R, Allen RP, Garcia-Borreguero D, Hening W, Walters AS, Mavraki E, Kirsch JM. The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting. Sleep Med. 2006 Jun;7(4):340-9. doi: 10.1016/j.sleep.2005.12.011. Epub 2006 May 19.</citation>
    <PMID>16713344</PMID>
  </reference>
  <reference>
    <citation>Kohnen R, Martinez-Martin P, Benes H, Trenkwalder C, Hogl B, Dunkl E, Walters AS. Validation of the Kohnen Restless Legs Syndrome-Quality of Life instrument. Sleep Med. 2016 Aug;24:10-17. doi: 10.1016/j.sleep.2016.04.019. Epub 2016 Aug 3.</citation>
    <PMID>27810174</PMID>
  </reference>
  <reference>
    <citation>Sforza E, Johannes M, Claudio B. The PAM-RL ambulatory device for detection of periodic leg movements: a validation study. Sleep Med. 2005 Sep;6(5):407-13. doi: 10.1016/j.sleep.2005.01.004. Epub 2005 Apr 1.</citation>
    <PMID>16139771</PMID>
  </reference>
  <reference>
    <citation>Garcia-Borreguero D, Kohnen R, Boothby L, Tzonova D, Larrosa O, Dunkl E. Validation of the Multiple Suggested Immobilization Test: A Test for the Assessment of Severity of Restless Legs Syndrome (Willis-Ekbom Disease). Sleep. 2013 Jul 1;36(7):1101-1109. doi: 10.5665/sleep.2820.</citation>
    <PMID>23814348</PMID>
  </reference>
  <reference>
    <citation>De Cock VC, Bayard S, Yu H, Grini M, Carlander B, Postuma R, Charif M, Dauvilliers Y. Suggested immobilization test for diagnosis of restless legs syndrome in Parkinson's disease. Mov Disord. 2012 May;27(6):743-9. doi: 10.1002/mds.24969. Epub 2012 Mar 21.</citation>
    <PMID>22437899</PMID>
  </reference>
  <reference>
    <citation>Marshall NS, Serinel Y, Killick R, Child JM, Raisin I, Berry CM, Lallukka T, Wassing R, Lee RW, Ratnavadivel R, Vedam H, Grunstein R, Wong KK, Hoyos CM, Cayanan EA, Comas M, Chapman JL, Yee BJ. Magnesium supplementation for the treatment of restless legs syndrome and periodic limb movement disorder: A systematic review. Sleep Med Rev. 2019 Dec;48:101218. doi: 10.1016/j.smrv.2019.101218. Epub 2019 Oct 16.</citation>
    <PMID>31678660</PMID>
  </reference>
  <reference>
    <citation>Hornyak M, Voderholzer U, Hohagen F, Berger M, Riemann D. Magnesium therapy for periodic leg movements-related insomnia and restless legs syndrome: an open pilot study. Sleep. 1998 Aug 1;21(5):501-5. doi: 10.1093/sleep/21.5.501.</citation>
    <PMID>9703590</PMID>
  </reference>
  <reference>
    <citation>Bartell S, Zallek S. Intravenous magnesium sulfate may relieve restless legs syndrome in pregnancy. J Clin Sleep Med. 2006 Apr 15;2(2):187-8.</citation>
    <PMID>17557494</PMID>
  </reference>
  <reference>
    <citation>Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington (DC): National Academies Press (US); 1997. Available from http://www.ncbi.nlm.nih.gov/books/NBK109825/</citation>
    <PMID>23115811</PMID>
  </reference>
  <reference>
    <citation>[The unveiling ceremony of the monument of the Unknown Nurse]. Noseleutike. 1992 Jan-Mar;31(139):19-23. No abstract available. Greek, Modern.</citation>
    <PMID>1596323</PMID>
  </reference>
  <reference>
    <citation>Coudray C, Rambeau M, Feillet-Coudray C, Gueux E, Tressol JC, Mazur A, Rayssiguier Y. Study of magnesium bioavailability from ten organic and inorganic Mg salts in Mg-depleted rats using a stable isotope approach. Magnes Res. 2005 Dec;18(4):215-23.</citation>
    <PMID>16548135</PMID>
  </reference>
  <reference>
    <citation>Lowenstein FW, Stanton MF. Serum magnesium levels in the United States, 1971-1974. J Am Coll Nutr. 1986;5(4):399-414. doi: 10.1080/07315724.1986.10720143.</citation>
    <PMID>3771947</PMID>
  </reference>
  <reference>
    <citation>Michaud M, Poirier G, Lavigne G, Montplaisir J. Restless Legs Syndrome: scoring criteria for leg movements recorded during the suggested immobilization test. Sleep Med. 2001 Jul;2(4):317-321. doi: 10.1016/s1389-9457(00)00072-1.</citation>
    <PMID>11438248</PMID>
  </reference>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>July 5, 2020</study_first_submitted>
  <study_first_submitted_qc>July 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2020</study_first_posted>
  <last_update_submitted>February 15, 2023</last_update_submitted>
  <last_update_submitted_qc>February 15, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OSF Healthcare System</investigator_affiliation>
    <investigator_full_name>Sasikanth Gorantla</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>RLS, Magnesium Citrate, Magnesium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Plan to share an abstract and data analysis results.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04462796
org study id: 1567451
nct id: NCT04462796
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The expected results of this study will have a significant impact on the treatment of RLS/WED
      patients. Magnesium supplementation (if proven to be beneficial) can be utilized as an
      inexpensive, safer, biologically plausible alternative to dopamine agonists and α2δ
      calcium-channel ligands.
This is an open-label, prospective, non-placebo controlled pilot study. 15 subjects with a
      diagnosis of restless legs syndrome (ICSD-3 diagnostic criteria) will be recruited from OSF
      Healthcare Saint Francis Medical Center sleep center and Illinois Neurological Institute.
      RLS/WED patients who meet inclusion and exclusion criteria during the initial clinic visit
      will be offered study participation. Standard treatment options will be discussed prior to
      the enrollment. Patients will be reassured that not participating in the study will not
      affect the future care they receive at OSF HealthCare. The potential risks and benefits of
      the study will be provided and, if the patient is interested, informed consent will be
      obtained. If the subject withdraws consent or does not finish both pre and post evaluation,
      we will replace the subject with another new recruit. The subject will come to the clinic for
      2 visits, a pre-magnesium visit and a post-magnesium visit. Following the completion of the
      pre-magnesium visit, the subject will be given 200 mg elemental magnesium daily (will be
      instructed to take with food at dinner) for 8 weeks. Both Visits the following study
      procedures will be performed: magnesium level, (International Restless Legs Syndrome) IRLS
      scale, Kohnen Restless Legs Syndrome Quality of Life Instrument (KRLS-QOL) scale and
      (Multiple Suggested Immobilization (MSI) test. The post magnesium visit will be schedule at
      the completion of the 8 week dose of magnesium.
allocation: N/A
intervention model: Single Group Assignment
intervention model description: Pilot study
primary purpose: Other
masking: None (Open Label)
measure: Subjective Improvement of Restless Legs Symptoms measured by the International Restless Legs Syndrome Scale (IRLS)
time frame: Completion of Study participation at 8 weeks
description: International Restless Leg Syndrome Scale. (IRLS) is a 10 question scale that subjects rate on a scale of 0-4; RLS can be classified as mild, moderate, severe and very severe, if the score is 0-10 (mild), 11-20 (moderate), 21-30 (severe) or 31-40 (very severe) respectively. The lower score reflects less symptom burden. Minimum score is 0 with a Maximum of 40.
measure: Subjective Improvement of Restless Legs Symptoms measured by the Kohnen Kohnen Restless Legs Syndrome Quality of Life Instrument (KRLS QOL)
time frame: Completion of Study participation at 8 weeks
description: Kohnen Restless Legs Syndrome Quality of Life instrument (KRLS QOL) is a self-administered validated patient-reported outcome measure with 12 questions that assess the quality of life in RLS patients. Scores range from 0-60.The lower score represents less impact of RLS symptoms on quality of life.
measure: Objective Improvement of Restless Legs Symptoms: Multiple Suggested Immobilization test (MSI) Score
time frame: Completion of Study participation at 8 weeks
description: Reduction in Multiple Suggested Immobilization test (MSI) discomfort Scores, range: 0-10, with a maximum total sum of 60 per hour. Three 1 hour trials will be conducted. Periodic limb movements during wakefulness will also be measured. Periodic limb movement index (PMLI) reflects periodic limb movements per hour. PMLI value of 0 indicates absence of limb movements and higher scores are often seen in patients with severe RLS
measure: Correlation of magnesium levels with Kohnen Restless Legs Syndrome Quality of Life Instrument (KRLS) and Multiple Suggested Immobilization test (MSI) scores
time frame: Completion of Study participation at 8 weeks
description: Assessment of Magnesium level, lab value will be assess. Normal values range from 1.6 - 2.6 mg/dl. The rationale of measuring serum magnesium level is to analyze whether serum magnesium levels correlate with other subjective and objective RLS outcome measures
arm group label: Magnesium Citrate
arm group type: Experimental
description: Magnesium Citrate given orally taken once daily for 8 weeks
intervention type: Dietary Supplement
intervention name: Magnesium Citrate
description: Magnesium Citrate 200 mg daily
arm group label: Magnesium Citrate
criteria: 
gender: All
minimum age: 18 Years
maximum age: 89 Years
healthy volunteers: No
last name: Sasikanth Gorantla, MD
role: Principal Investigator
affiliation: OSF Healthcare Saint Francis Medical Center
last name: Ashwath R Ravisankar, MBBS
phone: (309) 624-5422
email: ashwath.r.ravisankar@osfhealthcare.org
last name: Kimberly L Hartwig, RN, BSN
phone: (309) 655-4229
email: kimberly.hartwig@osfhealthcare.org
facility: 
status: Recruiting
contact: 
country: United States
url: https://aasm.org/clinical-resources/scoring-manual/
description: Manual used for scoring sleep and associated events
citation: Pratt DP. Restless Legs Syndrome/Willis-Ekbom Disease and Periodic Limb Movements: A Comprehensive Review of Epidemiology, Pathophysiology, Diagnosis and Treatment Considerations. Curr Rheumatol Rev. 2016;12(2):91-112. doi: 10.2174/1573403x12666160223120340.
PMID: 26902775
citation: Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997 Jan;12(1):61-5. doi: 10.1002/mds.870120111.
PMID: 8990055
citation: Coleman RM, Miles LE, Guilleminault CC, Zarcone VP Jr, van den Hoed J, Dement WC. Sleep-wake disorders in the elderly: polysomnographic analysis. J Am Geriatr Soc. 1981 Jul;29(7):289-96. doi: 10.1111/j.1532-5415.1981.tb01267.x.
PMID: 7240617
citation: Scofield H, Roth T, Drake C. Periodic limb movements during sleep: population prevalence, clinical correlates, and racial differences. Sleep. 2008 Sep;31(9):1221-7.
PMID: 18788647
citation: Garcia-Borreguero D, Guitart X, Garcia Malo C, Cano-Pumarega I, Granizo JJ, Ferre S. Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis. Sleep Med. 2018 May;45:94-97. doi: 10.1016/j.sleep.2018.02.002. Epub 2018 Feb 24.
PMID: 29680437
citation: Leu-Semenescu S, Petiau C, Charley Monaca C, Dauvilliers Y. French consensus: Augmentation syndrome in restless legs syndrome. Rev Neurol (Paris). 2018 Sep-Oct;174(7-8):532-539. doi: 10.1016/j.neurol.2018.06.004. Epub 2018 Jul 25.
PMID: 30055794
citation: Ito E, Inoue Y. [The International Classification of Sleep Disorders, third edition. American Academy of Sleep Medicine. Includes bibliographies and index]. Nihon Rinsho. 2015 Jun;73(6):916-23. Japanese.
PMID: 26065120
citation: Ferini-Strambi L, Aarskog D, Partinen M, Chaudhuri KR, Sohr M, Verri D, Albrecht S. Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med. 2008 Dec;9(8):874-81. doi: 10.1016/j.sleep.2008.09.001. Epub 2008 Oct 25.
PMID: 18952497
citation: Giorgi L, Asgharian A, Hunter B. Ropinirole in patients with restless legs syndrome and baseline IRLS total scores >/= 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension. Clin Ther. 2013 Sep;35(9):1321-36. doi: 10.1016/j.clinthera.2013.06.016. Epub 2013 Aug 9.
PMID: 23938061
citation: Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, Trenkwalder C; International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003 Mar;4(2):121-32. doi: 10.1016/s1389-9457(02)00258-7.
PMID: 14592342
citation: Abetz L, Arbuckle R, Allen RP, Garcia-Borreguero D, Hening W, Walters AS, Mavraki E, Kirsch JM. The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting. Sleep Med. 2006 Jun;7(4):340-9. doi: 10.1016/j.sleep.2005.12.011. Epub 2006 May 19.
PMID: 16713344
citation: Kohnen R, Martinez-Martin P, Benes H, Trenkwalder C, Hogl B, Dunkl E, Walters AS. Validation of the Kohnen Restless Legs Syndrome-Quality of Life instrument. Sleep Med. 2016 Aug;24:10-17. doi: 10.1016/j.sleep.2016.04.019. Epub 2016 Aug 3.
PMID: 27810174
citation: Sforza E, Johannes M, Claudio B. The PAM-RL ambulatory device for detection of periodic leg movements: a validation study. Sleep Med. 2005 Sep;6(5):407-13. doi: 10.1016/j.sleep.2005.01.004. Epub 2005 Apr 1.
PMID: 16139771
citation: Garcia-Borreguero D, Kohnen R, Boothby L, Tzonova D, Larrosa O, Dunkl E. Validation of the Multiple Suggested Immobilization Test: A Test for the Assessment of Severity of Restless Legs Syndrome (Willis-Ekbom Disease). Sleep. 2013 Jul 1;36(7):1101-1109. doi: 10.5665/sleep.2820.
PMID: 23814348
citation: De Cock VC, Bayard S, Yu H, Grini M, Carlander B, Postuma R, Charif M, Dauvilliers Y. Suggested immobilization test for diagnosis of restless legs syndrome in Parkinson's disease. Mov Disord. 2012 May;27(6):743-9. doi: 10.1002/mds.24969. Epub 2012 Mar 21.
PMID: 22437899
citation: Marshall NS, Serinel Y, Killick R, Child JM, Raisin I, Berry CM, Lallukka T, Wassing R, Lee RW, Ratnavadivel R, Vedam H, Grunstein R, Wong KK, Hoyos CM, Cayanan EA, Comas M, Chapman JL, Yee BJ. Magnesium supplementation for the treatment of restless legs syndrome and periodic limb movement disorder: A systematic review. Sleep Med Rev. 2019 Dec;48:101218. doi: 10.1016/j.smrv.2019.101218. Epub 2019 Oct 16.
PMID: 31678660
citation: Hornyak M, Voderholzer U, Hohagen F, Berger M, Riemann D. Magnesium therapy for periodic leg movements-related insomnia and restless legs syndrome: an open pilot study. Sleep. 1998 Aug 1;21(5):501-5. doi: 10.1093/sleep/21.5.501.
PMID: 9703590
citation: Bartell S, Zallek S. Intravenous magnesium sulfate may relieve restless legs syndrome in pregnancy. J Clin Sleep Med. 2006 Apr 15;2(2):187-8.
PMID: 17557494
citation: Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington (DC): National Academies Press (US); 1997. Available from http://www.ncbi.nlm.nih.gov/books/NBK109825/
PMID: 23115811
citation: [The unveiling ceremony of the monument of the Unknown Nurse]. Noseleutike. 1992 Jan-Mar;31(139):19-23. No abstract available. Greek, Modern.
PMID: 1596323
citation: Coudray C, Rambeau M, Feillet-Coudray C, Gueux E, Tressol JC, Mazur A, Rayssiguier Y. Study of magnesium bioavailability from ten organic and inorganic Mg salts in Mg-depleted rats using a stable isotope approach. Magnes Res. 2005 Dec;18(4):215-23.
PMID: 16548135
citation: Lowenstein FW, Stanton MF. Serum magnesium levels in the United States, 1971-1974. J Am Coll Nutr. 1986;5(4):399-414. doi: 10.1080/07315724.1986.10720143.
PMID: 3771947
citation: Michaud M, Poirier G, Lavigne G, Montplaisir J. Restless Legs Syndrome: scoring criteria for leg movements recorded during the suggested immobilization test. Sleep Med. 2001 Jul;2(4):317-321. doi: 10.1016/s1389-9457(00)00072-1.
PMID: 11438248
responsible party type: Principal Investigator
investigator affiliation: OSF Healthcare System
investigator full name: Sasikanth Gorantla
investigator title: Principal Investigator
mesh term: Psychomotor Agitation
mesh term: Restless Legs Syndrome
mesh term: Syndrome
mesh term: Magnesium citrate
sharing ipd: Undecided
ipd description: Plan to share an abstract and data analysis results.